Stock of the Day

Regulus Therapeutics (RGLS)

$8.24

+$0.14 (+1.7%)

Market Cap: $569.45M

About Regulus Therapeutics

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Recent News

• Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Preston Klassen Acquires 12,000 Shares (insidertrades.com)
• Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) (gurufocus.com)
• Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (seekingalpha.com)